Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

141.28AUD
18 Dec 2017
Change (% chg)

$1.25 (+0.89%)
Prev Close
$140.03
Open
$141.28
Day's High
$141.87
Day's Low
$140.22
Volume
493,050
Avg. Vol
751,279
52-wk High
$149.30
52-wk Low
$96.65

Chart for

About

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $63,331.20
Shares Outstanding(Mil.): 452.27
Dividend: 0.92
Yield (%): 1.06

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-CSL ‍Says Brian Mcnamee Will Assume Position Of Chairman-Elect​

* ‍JOHN SHINE AC HAS ANNOUNCED HIS INTENTION TO RETIRE AS CHAIRMAN​ Source text for Eikon: Further company coverage:

Dec 12 2017

Australia shares flat ahead of Fed rate decision, NZ up

Dec 11 Australian shares were flat on Monday as gains in the materials and energy sectors were negated by losses elsewhere as caution prevailed ahead of the U.S. Federal Reserve's rate rise decision later this week.

Dec 10 2017

BRIEF-CSL And HBM Portfolio Company Vitaeris Announce Strategic Partnership

* CSL AND HBM PORTFOLIO COMPANY VITAERIS ANNOUNCE STRATEGIC PARTNERSHIP WITH OPTION TO ACQUIRE Source text - http://bit.ly/2jhdF6b Further company coverage: (Gdynia Newsroom)

Dec 05 2017

BRIEF-CSL closes new US$700 million private placement in U.S.

* On 4 October, closed a new US$700 million private placement in U.S. Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-CSL receives US FDA approval of privigen for CIDP indication

* Has approved CSL Behring's Privigen for treatment of adults with chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability Source text for Eikon: Further company coverage:

Sep 14 2017

BRIEF-CSL's unit says ‍new phase III study shows significantly greater efficacy in children 6-24 months who receive AQIV​

* ‍New phase III study shows significantly greater efficacy in children 6-24 months who receive adjuvanted influenza vaccine (AQIV)​

Sep 11 2017

Fitch Assigns Christian Savings Limited 'B+' Rating; Outlook Positive

(The following statement was released by the rating agency) SYDNEY, August 31 (Fitch) Fitch Ratings has assigned Christian Savings Limited (CSL) a Long-Term Issuer Default Rating (IDR) of 'B+' with Positive Outlook. At the same time, Fitch also assigned the Short-Term IDR at 'B'. A full list of rating actions is at the end of this commentary. The assignment of CSL's ratings follows a reorganisation of the operating entity for the Christian Savings organisation. The organisation conducted its op

Aug 31 2017

BRIEF-CSL says CSL Behring acquires Calimmune

* Additionally, CSL Behring will acquire two proprietary platform technologies, Select and Cytegrity

Aug 27 2017

BRIEF-CSL says no share buyback is foreshadowed in FY18

* Co’s FY18 NPAT "expected to be in the range of about $1,480 million to $1,550 million at constant currency"

Aug 15 2017

BRIEF-CSL posts FY total revenue and other income of US$6,922.8 million

* FY total revenue and other income US$6,922.8 million versus versus US$6,129.2 million

Aug 15 2017

Earnings vs. Estimates